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Abstract
We provide both molecular and pharmacological evidence that the metabotropic, purinergic, P2Y6,
P2Y12 and P2Y13 receptors and the ionotropic P2X4 receptor contribute strongly to the rapid calcium
response caused by ATP and its analogues in mouse microglia. Real-time PCR demonstrates that the
most prevalent P2 receptor in microglia is P2Y6 followed, in order, by P2X4, P2Y12, and P2X7 =
P2Y13. Only very small quantities of mRNA for P2Y1, P2Y2, P2Y4, P2Y14, P2X3 and P2X5 were
found. Dose-response curves of the rapid calcium response gave a potency order of:
2MeSADP>ADP=UDP=IDP=UTP>ATP>BzATP, whereas A2P4 had little effect. Pertussis toxin
partially blocked responses to 2MeSADP, ADP and UDP. The P2X4 antagonist suramin, but not
PPADS, significantly blocked responses to ATP. These data indicate that P2Y6, P2Y12, P2Y13 and
P2X receptors mediate much of the rapid calcium responses and shape changes in microglia to low
concentrations of ATP, presumably at least partly because ATP is rapidly hydrolyzed to ADP.
Expression of P2Y6, P2Y12 and P2Y13 receptors appears to be largely glial in the brain, so that
peripheral immune cells and CNS microglia share these receptors. Thus, purinergic, metabotropic,
P2Y6, P2Y12, P2Y13 and P2X4 receptors might share a role in the activation and recruitment of
microglia in the brain and spinal cord by widely varying stimuli that cause the release of ATP,
including infection, injury and degeneration in the CNS, and peripheral tissue injury and
inflammation which is signaled via nerve signaling to the spinal cord.
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INTRODUCTION
Investigators have hypothesized recently that microglia, the major intrinsic immune competent
cells of the brain and spinal cord, play a major role in enhancing the long-term pain that
accompanies nerve injury and peripheral tissue injury and inflammation (Colburn et al.,
1999; Arruda et al., 2000; Fu et al., 2000; Watkins et al., 2001a; Watkins et al., 2001b;
Svensson et al., 2003; Tsuda et al., 2003; Raghavendra et al., 2004). However, the mechanisms
by which peripheral injury and inflammation recruit and activate the normally ‘resting’
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microglia (Streit et al., 1988) and the mechanisms by which activated microglia enhance pain
are only poorly understood. Our laboratory (Wu et al., 2004) recently determined that P2
receptors are likely mediators for both the activation of microglia and long-term pain caused
by peripheral injury. Tsuda et al. 2003 suggest that activating P2 receptors on microglia is also
at least partly responsible for neuropathic pain. To further understand which P2 receptors on
microglia are responsible for the activation of microglia we conducted the present molecular
and functional experiments.
Although many cytokines including fractalkine can activate microglia (reviewed in Hanisch,
2002), another substance that is released in relatively high concentrations by all tissues
following all types of injury is adenosine triphosphate (ATP). In addition, ATP is released by
primary afferents and by astrocytes under several circumstances (Salter et al., 1993; Hassinger,
et al., 1996; Bardoni et al., 1997; Guthrie, et al., 1999). It has been suggested that ATP and its
metabolites might be used for communicating between different glia types and neurons
(Hansson and Ronnback, 2003). Thus, it might be that injury and inflammation utilize ATP to
coordinate the activation of neurons, astrocytes and microglia to centrally enhance pain
signaling.
Tsuda et al. 2003 and Inoue et al. 2004 suggest that ATP acting via the P2X4 purinergic receptor
might have a major role in activating microglia and causing enhanced pain following spinal
nerve injury. However, other labs have suggested that functional metabotropic P2Y receptors
including P2Y12 receptors mediate the chemotaxis that occurs during activation (Moller et
al., 2000; Honda et al., 2001). Our laboratory has also suggested that P2Y receptors might play
a role in activation of microglia and long-term pain following formalin injection into the paw
in rodents (Wu et al., 2004). A recent report (Bianco et al., 2005) suggests that all P2X and
P2Y receptors are expressed by microglia, based on rtPCR. However, this group relied on
microglia cell lines for most of the PCR data.
In this report, we have used rtPCR and real-time quantitative PCR to demonstrate that P2Y6,
P2Y12, P2Y13 and P2X4 receptors are expressed in mouse microglia in culture, and in the
mouse spinal cord and brain. Real-time quantitative PCR demonstrates that some P2Y and
P2X receptors have low expression in microglia, whereas those listed above are abundantly
expressed. We also used agonists and antagonists that activate rapid increases in intracellular
calcium and rapid shape changes in microglia to conclude that either ATP or its metabolite
ADP activates purinergic receptors with properties that are most like the newly cloned
P2Y12, and P2Y13 receptors in addition to P2Y6 and P2X4 receptors. We also confirm that
activation of the P2X7 receptor might occur at higher, but physiological, doses of ATP and can
lead to more sustained increases in intracellular calcium (Ferrari et al., 1996; Ferrari et al.,
1997; Verderio and Matteoli, 2001).
OBJECTIVE
To determine the molecular P2 receptor subtypes in mouse microglia in culture and the
functional expression of the P2 receptor subtypes using selective agonists and antagonists, and




All guidelines required by University of Utah’s and University of North Carolina’s IACUCs
were followed in harvesting tissues. Glia were obtained from P0–P7 C57BL/6 mouse pups
using the methods described previously (Guthrie et al., 1999). Briefly, cortices were removed,
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cleaned of meninges and trypsinized, and triturated to dissociate. Cells were plated in culture
flasks at 50 000 cells cm2, and grown in modified eagles medium (MEM), 10% fetal calf serum,
penicillin and streptomycin, essential amino acids and nonessential amino acids. Microglia
were harvested from astrocytes that were confluent and not more than 3-weeks old. Passaging
microglia was accomplished by shaking and slapping the flask on a table, several times and
vigorously swirling the flasks to dislodge microglia attached to the monolayer of astrocytes.
The growth medium containing the dislodged microglia cells was centrifuged at 800 rpm for
5 minutes. Following centrifugation, most of the supernatant was removed and the cells in the
pellet were resuspended in the remaining 2–3 ml, yielding a density of ~85 000 cells ml−1. The
density of cells was ~20 000 cells cm2 after plating.
Cells were passaged into wells of a Falcon 24- well Multiwell plate (35-3047). Each well was
pretreated with 266 μg ml−1 poly-L-lysine then dried. Silicone gaskets with an inner diameter
of 4 mm were used to reduce the plating surface in each well. 20–30 μl of microglia suspension
was placed into the center of each gasket of 12 wells in each multiwell plate. Multiwell plates
were placed in the incubator for 1 hour, then 1 ml MEM + 10% FBS was added. All above
procedures were conducted at 37°C, with 5% CO2 atmosphere. Microglia purity was assessed
using GSA-IB4 lectin, and OX-42-antibody- (Serotec) labeling, which labels the CR3 receptor.
These indicated >90% pure microglia with astrocytes, and oligodendroglia as the most common
contaminants. Ca2+ responses from non-microglia were not included in the data analysis.
Observations were made 4 hours and 24 hours after passaging.
RNA expression
Cultures—Microglia from mouse brain were prepared and partially isolated as described
above (>90% microglia/ <10% astrocytes and oligodendrocytes). In addition, the culture bed
(astrocytes, microglia, oligodendrocytes and a few neurons) was also detached from the culture
flasks with trypsin and pelleted. Total RNA was isolated from the cells using the RNAeasy
extraction kit from Qiagen and rtPCR was performed on 1 μg of total RNA, for 37 cycles: each
cycle was 95°C for 14 seconds, 57°C for 30 seconds, then 68°C for 1 minute. PCR primers for
P2Y receptors were designed from the genomic sequences obtained from the NCBI GenBank
sequence database. Table 1 lists the characteristics of these primers. Analysis of 5 μl of the
PCR product was by electrophoresis on agarose gels with ethidium bromide.
Brain—Total RNA was extracted from brain and spinal cord tissue following perfusion with
0.1 M phosphate buffered saline using TRIZOL reagent (Invitrogen). We performed rtPCR
and analyzed as described for the cell-culture RNA above. Primers coding for larger products
for P2Y12 and 13 were used for the brain extracts to ensure specificity. Product from these
gels was sequenced and returned results >95% identical to the known sequences for PY12 and
13.
Real-time PCR—In addition to microglia, harvested as described above, ‘mixed glia’ (mostly
astrocytes and microglia) and ‘purified microglia’ (>90% microglia by visual inspection) were
prepared. All harvest types were reduced to a pellet plus a minimum amount of medium (10–
30 μl), 5 μl RNAse-out (Invitrogen 10777-019) and 50 μl RNA-Later (Qiagen 1017980) was
added and mixed quickly before quick freezing in a dry ice/methanol slurry. Mixed glia were
harvested from monolayers after first shaking the flask to remove loose and suspended
microglia. Flasks were then quickly rinsed with 5 ml 0.05% Trypsin/EDTA Invitrogen
25300-054), and incubated in 5 ml fresh 0.05% Trypsin/EDTA. Cells loosened by Trypsin
treatment were centrifuged and quick frozen as described above. To harvest ‘purified
microglia’, four microglia pellets from 75 cm2 flasks were passaged into one 25 cm2 flask in
3 ml MEM and FBS, and incubated for 4 hours at 37°C. Following incubation the cells loosened
by shaking were centrifuged and quick frozen as described above.
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The brain and spinal cord were also removed from adult mice euthanized with an overdose of
Halothane, and the cerebral cortex and spinal cord quickly removed and frozen in liquid
nitrogen. Following thaw in RNeasy disruption buffer, samples were homogenized using
pipettes. For both preparations, the protocol below was followed.
RNA was extracted from frozen pellets using the RNeasy Mini Kit (Qiagen 74104).
Immediately following RNA extraction and purification, extracts were converted to cDNA
using the SuperScript III First-Strand Synthesis System for rtPCR (Invitrogen 18080-051).
DNA concentrations were determined using OD measurements. The cDNA libraries were
analyzed using the ABI quantitative real-time PCR system on the ABI Prism 7900 Sequence
Detection System (Advanced Biosystems Inc.). ABI supplied ‘Taqman Gene Expression
Assay’ primer and probe sets (both standard and custom) for P2Y1, P2Y2, P2Y4, P2Y6,
P2Y12, P2Y13, P2Y14, P2X3, P2X4, P2X5, P2X7, glial filament acidic protein (GFAP), β-Actin
(Act b), toll-like receptor 4 (tlr-4) and CD14 (see Table 2 for specific primers) were used with
ABI Taq-Man Master mix. Template concentrations were normalized prior to addition to
reaction wells in a 96-well reaction plate. Each sample was run in triplicate with one ‘no-
template’ control. GFAP was used to assess the degree of astrocyte presence in the purified
microglia samples from which total RNA was extracted. In addition, Mac-1 (CR3 receptor),
(tlr-4) and CD14 mRNA expression were assessed as markers for microglia (CD14 antigen is
part of the functional heteromeric lipopolysaccharide (LPS) receptor complex comprised of
CD14, tlr4 and MD-2) (Underhill and Ozinsky, 2002).
The relative amount of astrocyte and microglia markers, and P2Y and P2X receptor RNA was
computed using the Standard Curve Methods and Comparative Ct Methods described in
Applied Biosystems User Bulletin #2.
Statistical analysis consisted of one way analysis of variance followed by comparisons to
control using Dunnet’s test.
Calcium imaging—All experiments were performed on a calcium-imaging setup consisting
of a Nikon DiaPhot 300 microscope with custom-built epifluorescence illumination.
Illumination wavelength and intensity were controlled using a computer-controlled filter
wheel. Images were acquired with a Photometrics cooled CCD camera employing a Kodak
KAF-1400 chip (Roper Scientific). The microscope, camera and manipulators were mounted
on a vibration isolation table (Newport Corp.).
Cells were loaded for 30–50 minutes in growth medium containing the calcium indicator fluo-3
AM (3 μM; Molecular Probes), washed two times with observation medium, then allowed 20–
30 minutes to de-esterify and to come to room temperature. Other experiments used fura-4,
loaded similar to the description above, as the calcium indicator. These experiments provided
more quantitative data on intracellular calcium concentrations. Sequences of images were
acquired at 1.5-second intervals. Control intensities were based on 7–15 images collected
before drug administration. The control images were also used to identify the positions of cells
according to minimum intensity and minimum size criteria; high-pass filtered images were
used to help define the borders of the cells. The average intensity of each cell (usually 100–
200 cells field−1) was measured in each image of the sequence. The criterion for a positive
response was set at a fluorescence intensity exceeding the control values by at least 2 standard
deviations of those control values for at least two consecutive frames.
Drug administration—Drugs were administered via a custom chamber lowered into each
well of the multiwell plate, which prevented changes in the liquid level within the well. The
flow of drug solution was controlled with a peristaltic pump that delivered enough solution
through the well to completely replace the well volume in 15 seconds. The well was perfused
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throughout the entire observation period. The perfusion system was rinsed thoroughly between
applications. All calcium-imaging experiments were performed in observation medium (MEM
with 10 mM Hepes and 25 mM glucose, pH 7.3) at room temperature.
Agonists used: UTP, UDP, ATP, ADP, 2-methylthio-ADP (2MeSADP), 2′,3′-O-(4-benzoyl-
benzoyl) adenosine 5′-triphosphate (BzATP), adenosine 5′-O-(2-thiophosphate) (ADPβS)
P1,P4-di-adenosine-5′ tetraphosphate (A2P4). Antagonists used: oxidized ATP (o-ATP), 2′-
deoxy-N6-methyladenosine-3′,5′-bisphosphate (MRS 2179), P1,P4-di-adenosine-5′
tetraphosphate (A2P4). All drugs were diluted in observation medium (see above). 2MeSADP
and pyridoxal-5′-phosphate-6-azophenyl-2′,4′-disulphonic acid (PPADS) were obtained from
RBI. All other nucleotides and suramin were obtained from Sigma. All nucleotides were
purchased at the highest purity available. Pertussis toxin (PTx) was obtained from BIOMOL
Laboratories (Plymouth Meeting).
Shape changes—Phase-contrast micrographs of the region analyzed for rapid calcium
increases (comprising 50–300 cells) were taken before and after administration of agonists.
These photomicrographs were analyzed in Photoshop, overlaying the before photo with the
after photo, with variable opacity applied. Changes in shape and movement (changes in
location) were detected easily in these overlays. Changes in shape were graded on a five-point
scale by an observer blinded to the treatments in which 0 = no change, 1 = changes in shape
in <10% of the cells, 2 = changes in 10–20% of the cells, 3 = changes in 20–40% of the cells,
4 = changes in >40% of the cells, and 5 = changes in all cells in the field.
Statistical comparisons were made using one way analysis of variance, and individual
comparisons made using Student’s t-test with significance accepted at P<0.05.
RESULTS
Microglia plated for 4 hours had few processes and resembled activated microglia described
by other groups (Fig. 1, right). By 24 hours most microglia had many processes and resembled
the more ‘resting-like’ morphology noted by Möller et al. 2000 when microglia were grown
in activated astrocyte medium (Fig. 1, left). In preliminary experiments, we kept careful track
of the types of microglia (e.g. highly processed, round, highly phase-bright, heavy labeling
with IB4 lectin or complement receptor antibodies OX-42, Mac-1) that demonstrated calcium
responses to ATP, and found no correlation between the shape and the responses at any dose
of ATP. We also cultured microglia in different concentrations of glycine and serine to
determine if these amino acids, which are purported to adjust the activation state of microglia,
had an effect on the ATP induced calcium response, and did not observe a major effect. We
did, however, observe that cultures passaged for >4 days were less responsive than cultures
observed at either 4 hours or 24 hours.
Receptor mRNA expression
Using rtPCR, we demonstrated that microglia cultures from mouse express RNA that encodes
P2Y6, P2Y12 P2Y13 and P2X4 receptors (Fig. 2). Because the microglia cultures contain small
numbers of astrocytes and oligodendroglia (<10% contamination), we compared the expression
of P2Y receptors with the astrocyte cultures from which the microglia were harvested. Fig. 2
indicates that these mixed glial cultures express P2Y1, P2Y2, P2Y6, P2Y12 and P2Y13 and
P2X4 receptor RNA. We also performed rtPCR on RNA extracts from whole mouse brain, and
demonstrated the expression of both P2Y12 and P2Y13 receptor RNA (Fig. 3). However, rtPCR
gave variable results, making it difficult to determine which of these receptors were expressed
by microglia and which by astrocytes.
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Using semi-quantitative rtPCR, we noted the presence of GFAP and P2Y1 mRNA in the
microglia preparations, and the bands of the various P2Y receptors varied from run to run. To
get a better idea of the relative amounts of each of these receptor mRNAs, we used real-time
PCR. As shown in Fig. 4, the expression of P2Y6, P2Y12, P2Y13 and P2X4 purinergic receptors
in purified microglia is much higher than in the mixed glial cultures from which they were
isolated. The mixed glial cultures from which the microglia were harvested had much greater
expression of GFAP mRNA and less of the above receptors and the microglia markers Mac1
and CD14 (but not tlr-4) (Fig. 4). The mixed cultures also expressed more P2X7, which
indicates that at least some of the P2X7 receptor is expressed by astrocytes.
Comparing the relative amounts of purinergic receptor mRNA in microglia and mixed glial
cultures using the Comparative Ct Method, the most abundant purinergic receptor mRNA in
microglia is P2Y6 followed by P2X4, P2Y12, and P2X7 = P2Y13 (Fig. 4). Because small
amounts mRNA encoding other P2Y receptors (all normalized to β-actin) (P2Y1, P2Y2 and
P2Y4) and P2X receptors (P2X3, 1 × 10−5 in astrocytes and not detectable in microglia;
P2X5, 8 × 10−6 in astrocytes and 8 × 10−8 in microglia) were measured in purified microglia,
in this state of activation at least, these receptors are most likely on either astrocytes or
oligodendrocytes but not on microglia. P2Y14, which is the UDP-glucose receptor, is probably
located on both astrocytes and microglia (1.2 × 10−4 in astrocytes and 1.1 × 10−5 in microglia).
Extracts from cerebral cortex and spinal cord from adult mice were also used for real-time PCR
(Fig. 5). Note that the amounts of mRNA for each P2 receptor are in the same order of
magnitude as that in mixed astrocyte/microglia cultures. The relative amounts of each receptor
are also similar except for P2Y6 which is less abundant in cortex and spinal cord, and P2Y12
which is more abundant in cortex and spinal cord.
Calcium dose-response
Microglia plated for either 4 or 24 hours demonstrated rapid, dose-related increases in
intracellular free calcium levels in response to ATP. In some dishes, >85% of the microglia
responded to 10 μM ATP. On average, 44% of microglia demonstrated a significant increase
in intracellular free calcium in response to 50 nM ATP, whereas microglia did not respond to
the vehicle alone.
Dose-response curves (Fig. 6) indicate that the intracellular calcium response was most
sensitive to 2MeSADP. At 4 hours after plating, EC50 values for each agonist were: 2MeSADP,
~8.6; UDP, ~8.3; UTP, ~8.3; IDP, ~7.8; ADP, ~7.8; and ATP, ~6.2. (−log10 EC50 molar
values). At 24 hours after plating, EC50 values for each agonist were: 2MeSADP, ~9.3; UDP,
~7.6; ADP, ~7.5; UTP, ~7.3; ATP, ~6.5; and BZATP, ~5.7. Fitting these data to curves based
on single-receptor kinetics revealed good fits for UTP and ATP, and approximate fits for UDP,
ADP and 2MeSADP. The sensitivity of the agonists is also indicated by the Kd values derived
from the 24-hour curves: 2 MeSADP, 14 nM; ADP, 70 nM; UDP, 70 nM; UTP, 240 nM; ATP,
1.5 μM; and BzATP, 13 μM.
To test the specificity of microglial responses to ATP, we tested other purinergic receptor
agonists and agents that cause rapid calcium increases in astrocytes. Adenosine (100 μM) did
not evoke calcium increases. These same wells of microglia responded well to application of
2 μM ATP (data not shown). The non-hydrolyzable ADP-like agent, ADPβS (10 μM) caused
a rapid calcium increase in the majority of microglia, confirming that ADP is likely to be the
active agent when ADP is applied.
Glutamate (1 mM) and KCl (60 mM) caused a gradual increase in intracellular Ca2+ in
microglia in some dishes, but <10% of the microglia in these dishes showed any Ca2+ changes.
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These slow changes are different from the characteristically rapid response to ATP and other
purinoceptor agonists.
P2 receptor antagonists
The responses to ADP and UDP indicate involvement of P2Y receptors. This is further
supported by data showing that 100 μM PPADS (which blocks most P2X receptors and blocks
calcium waves in astrocytes) had little effect on ATP induced calcium increases in microglia
(Fig. 7). Conversely, 100 μM suramin, which is a more general blocker of purinergic receptors
and is effective at most P2Y receptors, significantly inhibits the calcium response to ATP in
microglia.
Additional evidence that P2Y receptors are at least partially involved is the finding that PTx
significantly reduces the calcium response to 2MeSADP, ADP and UDP (P<0.05), indicating
G-protein mediation of the Ca2+ response and that ionotropic P2X receptors have only a partial
role in the responses to these agonists (Fig. 7). It is unlikely that the P2Y1 receptor is involved
because mRNA expression in microglia is low and the specific P2Y1 receptor antagonist, MRS
2179 (30 μM) had no effect on the responses induced by 2 MeSADP, ADP and UDP (Fig. 8).
However, this dose of MRS 2179 blocks calcium waves in astrocytes, which are thought to be
mediated largely by P2Y1 receptors).
In addition to P2Y receptors, the response to BZATP indicates P2X7 receptor involvement at
relatively low concentrations of ATP compared with other reports. This is further indicated by
the effects of o-ATP, a specific P2X7 receptor antagonist. As shown in Fig. 8, o-ATP
significantly reduces the response to 10 μM ATP, but only slightly (and non-significantly)
reduces the response evoked by 100 nM ATP.
This is consistent with the hypothesis that 10 μM ATP activates P2X7 receptors but 100 nM
ATP does not.
Shape changes
Each agonists, except UTP and UDP, caused significant shape changes within 5 minutes of
application. Shape changes included extension of filopodia, ruffling of the edges, overall
flattening of the cells, and obvious rapid movement. In addition, phase contrast was often
reduced after application of agonists, which is, apparently, related to the loss of intracellular
membranous inclusions. The dose-response curves for shape changes are shown in Fig. 9. The
rank order for the potency of the agonists to cause shape changes was similar to that causing
Ca2+ increases with 2MeSADP>ADP>ATP. However, both IDP and UTP produced fewer
maximal responses than the other agonists, and no responses were observed with UDP. This
indicates that P2Y13 (which is normally activated by IDP) and P2Y6 (which is activated
strongly by UDP) might play a lesser role in causing shape changes than in inducing rapid
calcium changes.
CONCLUSIONS
• Real-time PCR confirms the presence of mRNA that encodes P2 receptor subtypes
and with relative abundance P2Y6>P2X4>P2Y12>P2X7=P2Y13 in mouse microglia
in culture.
• Full dose-response curves of rapid calcium increases demonstrate that the order of
agonist potency is 2MeSADP >UDP=ADP=IDP=UTP>ATP>BzATP, which
indicates that each of the above receptors contributes to the rapid calcium responses
observed in cultured mouse microglia
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• P2 receptor agonists cause shape changes at similar doses, which indicates that these
effects are caused by activating receptor subtypes similar to those that cause rapid
calcium increases in mouse microglia
• Real-time PCR shows little, if any, mRNA that encodes P2X3, P2X5, P2Y1, P2Y2,
and P2Y4 receptors in mouse microglia.
DISCUSSION
The results presented here predict that both P2Y and P2X receptor subtypes have a role in the
activation of microglia by nucleotides that are released from either primary afferents or
astrocytes following injury and inflammation that is signaled from the periphery, or locally
released by brain or spinal cord injury. We have shown using real-time PCR that the most
abundant P2 receptors in microglia are P2Y6, followed by P2X4>P2Y12>P2X7=P2Y13; these
pharmacological data also indicate that each of these receptor subtypes might contribute to the
rapid calcium increases in microglia evoked by nucleotides.
mRNA expression
The results of this paper place P2Y6, P2Y12, P2Y13, P2X7, and P2X4 receptors in mouse brain
microglia, which confirms previous studies (Zhang et al., 2002; Tsuda et al., 2003). In addition,
the present data suggest that astrocytes express P2Y1 and P2Y2 receptors (also suggested by
Jimenez et al., 2000; Fumagali et al., 2003; Franke et al., 2004). There was very little expression
of P2Y4 receptors in mixed cultures, and even less in purified microglia, indicating that either
expression is low in astrocytes or expression by cellular contaminants (either oligodendrocytes
or neurons) in the mixed glial cultures. Recently, others have also shown that P2Y12 and
P2Y13 receptors are expressed in brain (Fumaglia et al., 2004; Hollopeter et al., 2001; Laitinen
et al., 2001; Sasaki et al., 2003). Although Bianco et al. 2005 provide evidence that all
mammalian P2 receptors are expressed in mouse microglia and that these receptors are
differentially expressed in activated compared with resting microglia, our data do not confirm
their results. Instead, several of P2 receptor subtypes have little expression in microglia. These
differences probably occur because Bianco et al. used an immortalized cell line for some
analyses and relied on rtPCR for detection. Although our rtPCR showed similar results, these
were refined further by the more quantitative real-time PCR. This latter technique indicates
that P2X3, P2X5, P2Y1, P2Y2, and P2Y4 receptors are expressed not by microglia but by other
cells in astrocyte/microglia mixed cultures.
Thus, microglia resemble peripheral immune cells in which P2X4, P2Y13 and P2Y6 receptors
occur. Interestingly, P2Y12 receptors are expressed highly by platelets, and have been localized
to immune cells recently (Jin et al., 1998; Fumaglia et al., 2004; Wang et al., 2004).
Rapid Ca2+ responses
The potent response to 2MeSADP and ADP indicates the involvement of either P2Y12 or
P2Y13 receptors, the later of which is emphasized because of the response to IDP (Holopeter
et al., 2001; Zhang et al., 2002). The inflection in the 24 hour 2MeSADP curve is consistent
and might be caused by the recruitment of additional receptor(s), for example P2Y6 receptors,
at micromolar doses. The more prominent inflection at 24 hours might reflect alterations in
receptor expression over time, a possibility we are investigating currently. The robust response
to UDP also indicates P2Y6 receptor involvement. The response to UTP is puzzling because
it is proposed to be most potent at activating P2Y2 and P2Y4 receptors, which are essentially
not expressed by microglia (see real-time data). Part of the response to UTP might be caused
by hydrolysis of UTP to UDP but, if so, we would expect the response to UTP to be smaller
than that to UDP. Others have also observed robust responses to UTP (Möller et al., 2000).
The response to A2P4 was variable, and in <20% of the cells, even at the highest doses in
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microglia plated for either 4 or 24 hours. The lack of a robust response to A2P4 indicates weak
involvement of P2X4 and P2Y12 receptors, but might also result from antagonism by A2P4 of
the P2Y13 receptor (Marteau et al., 2001; Patel et al., 2001) coupled with agonist action at
P2X4 receptors. Although responses to all other agonists were also similar at both 4 hours and
24 hours after plating microglia, with the exception of the response to 2MeSADP, they were
somewhat more robust at 4 hours, indicating possible downregulation with time after plating.
The order of effectiveness of purinergic agonists on Ca2+ responses,
2MeSADP>UDP=ADP=IDP=UTP>ATP, is most consistent with activation of P2Y12
receptors, which have been cloned recently. These receptors are most sensitive to 2MeSADP
and ADP, and less sensitive to ATP (reviewed by Communi et al., 2001; Foster et al., 2001)
(Hollopeter et al., 2001; Nicholas, 2001). However, responsiveness to UDP also indicates a
contribution from P2Y6 receptors. Sasaki et al. 2003 also suggested a role for P2Y12 receptors
based on rat-brain mRNA expression and in situ hybridization. The sensitivities to ADP and
IDP also indicate partial involvement of P2Y13 receptors in the generation of the rapid Ca2+
responses (Fumaglia et al., 2004). Although P2Y1 receptors have a similar pharmacological
profile to these agonists (Lazarowski et al., 2001), our data indicate that they probably do not
play a role because little P2Y1 mRNA is expressed in microglia, and PPADS and the
prototypical P2Y1 receptor antagonist MRS2179 do not block the calcium responses.
The prominence of the response to 2MeSADP, the lack of response to A2P4, and the lack of
blockade by PPADS indicate that P2X4 receptors do not dominate the rapid Ca2+ response.
However, PTx does not abolish completely the Ca2+ response, and the fairly robust response
to ATP indicates a substantial contribution from P2X4 receptors for which mRNA expression
is also robust.
The sensitivity to ADP and the lack of response to adenosine rules out adenosine receptors in
mediating the rapid Ca2+ responses. The ability of suramin, but not PPADS, to block responses
to ATP rules out most of the other P2X receptors as does the partial blockade of responsiveness
by PTx. However, these data are consistent with P2Y6, P2Y12 and P2Y13 receptor activation
mediating the rapid Ca2+ responses.
Shape changes
It appears that rapid Ca2+responses are not always linked to shape changes and resultant
chemotaxis. UTP and UDP activate rapid Ca2+responses readily, but do not cause robust shape
changes.
Ca2+ responses to UTP in microglia, as observed in this report, have been demonstrated
previously (Möller et al., 2000). However, apparently UTP does not activate the same cellular
effects as ATP and ADP such as chemotaxis and the release of interleukin 6 (IL-6) (Norenberg
et al., 1997; Honda et al., 2001; Shigemoto-Mogami et al., 2001), which indicates that
activating different receptor subtypes has different effects on cell function. Heterogeneity in
microglial responses has been reported by Möller et al. 2000 who suggest that different states
or populations of microglia express different P2Y receptors. They specifically suggest that
expression of P2Y receptors decreases in activated microglia. Of course, the response profiles
of the agonists and antagonists applied here might also be explained by microglial-specific
effects of these receptor subtypes, splice variants, heterodimerization of more than one receptor
subtype, and by the existence of an unidentified P2Y receptor (e.g. Ferrari et al., 1996; Ferrari
et al., 1997; Ferrari et al., 1999). For example, cloning of the P2Y14 receptor was reported
recently, and Bianco et al. 2005 report the presence of this receptor on microglia, which we
have confirmed with real-time PCR (data not shown). However, the P2Y14 receptor is not
expected to contribute to the pharmacological profile reported here because it is activated
preferentially by glucose compounds.
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The pore-forming P2X7 receptor
Our data indicate that the pore-forming P2X7 receptor is expressed by both astrocytes and
microglia.
The prototypical P2X7 agonist BzATP evoked a large, rapid Ca2+ increase in microglia,
indicating possible activation of P2X7 receptors with higher doses of ATP. The P2X7
antagonist, o-ATP, significantly reduced the ATP responses, and BzATP activated the Ca2+
response at doses consistent with P2X7 receptor activation. The addition of a longer lasting
Ca2+ increase at higher doses of ATP also hints at the activation of additional receptors with
increasing concentrations of ATP. This is not unexpected given previous reports (Ferrari et
al., 1996; Ferrari et al., 1997; Ferrari et al., 1999; Visentin et al., 1999; Hide et al., 2000; Inoue
et al., 1998) indicating that doses of ATP as low as 10 μM might activate P2X7 receptors.
However, most of the effects that are attributed to P2X7 recetors are thought to occur at
millimolar doses. We suggest that activation of the P2X7 receptor at low doses of ATP occurs
without pore formation as suggested by Gudipaty et al. 2001 because 100 μM ATP application
for one hour does not lead to cell lysis. With higher (millimolar) doses of ATP we observe cell
lysis, as observed by others (data not shown).
Functional significance
Microglia are present in large numbers throughout the normal CNS. Normally, they are in a
‘resting’ state in which they have highly ramified, large, non-overlapping dendritic
distributions, and express few markers of their immune cell lineage (Pennell and Streit,
1998). They are activated rapidly following either injury or infection of the CNS (e.g. Streit
et al., 1999). Very recently, they have also been shown to be activated rapidly in specific regions
of the spinal cord and brain that receive inputs from either noxious or inflammatory insults to
the periphery, under conditions in which degeneration of spinal cord elements are unlikely
(Fu et al., 1999; Fu et al., 2000; Fu et al., 2001; Sweitzer et al., 1999; Raghavendra et al.,
2004). It appears that this activation is most likely to be mediated by neural signaling from the
peripheral inflammation site to the CNS.
The in vivo mediators of this rapid activation caused by injury outside the CNS are unknown.
Many substances released by injury have been shown to cause appropriate changes in
microglia, including transforming growth factor α (TGF-α), C5a, EGF, fractalkine and ATP
(Yao et al., 1990; Hayashi et al., 1995; Nolte et al., 1996; Nolte et al., 1997; Cross and
Woodroofe, 1999; Honda et al., 2001; Chen et al., 2002). One substance that might mediate
both neuronally mediated and injury-induced activation is ATP (Zimmermann 1994). ATP has
long been known to be released by injury and infection in tissues of all kinds. In addition, ATP
is released by presumed nociceptive afferents in the spinal cord (Bardoni et al., 1997).
Following noxious events in the periphery, primary afferent nociceptors might release either
ATP or other cytokines in the spinal cord, which result in activation and recruitment of
microglia to the vicinity of the released ATP. In addition, astrocytes are activated rapidly by
noxious events signaled from the periphery (Garrison et al., 1994; Watkins et al., 2001a;
Watkins et al., 2001b). It is possible that activation of astrocytes might also cause the release
of ATP, either as individual events or as part of an astrocyte Ca2+ wave, which have been
observed in culture and, recently, in brain slices in vitro (Cornell-Bell et al., 1990; Venance
et al., 1998; Newman, 2001; Schipke et al., 2001). This additional, astrocyte-derived ATP
might further enhance the possibility of activation and recruitment of microglia into the vicinity
of the spinal cord where primary afferent nociceptors terminate as well as causing the release
of neurally active cytokines by microglia (Ferrari et al., 1996; Ferrari et al., 1997; Inoue et
al., 1998; Hide et al., 2000; Sanz and Di Virgilio, 2000; Honda et al., 2001; Shigemoto-Mogami
et al., 2001).
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The significance of activation and recruitment of microglia in pathological and pain states is
unknown presently, but is postulated to be either destructive or protective. Most recently, both
contributions have been predicted, depending on when and to what state microglia are activated
(Streit et al., 1999). In pain models, activation of microglia correlates with the timing of
enhanced, persistent pain. Thus, it is possible that microglia play a role in enhancing pain by
participating in a cytokine cascade similar to that mediated in the periphery by macrophages
(Fu et al., 2000; Fu et al., 2001). The microglia receptors that contribute to this activation are
likely to be both P2X (Tsuda et al., 2003) and P2Y (Wu et al., 2004) receptors. Our hypothesis
is that injury and inflammation in the periphery activates nociceptive primary afferents that
release ATP in the spinal dorsal horn. This ATP release activates astrocytes and microglia.
Astrocytes release more ATP, recruiting more activated microglia. Activated microglia release
TNFα, IL-6 and other cytokines, which enhance synaptic transmission of nociceptive inputs
in the dorsal horn increasing the nociceptive signal to higher brain centers, resulting in
enhanced pain. This hypothesis predicts that P2 receptor antagonists that are either applied to
or reach the spinal cord systemically, might be useful in treating pain enhanced by injury and
inflammation.
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Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Phase-contrast photomicrographs of microglia
Both round, highly phase-bright microglia and multiprocessed microglia are visible. After
plating for 4 hours (right), fewer microglia exhibit long branching processes than after 24 hours
(left).
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Fig. 2. rtPCR gel of P2 receptors from astrocytes and microglia in culture
Note the presence of P2Y1 and P2Y2 receptors and GFAP in the mixed, astrocyte and microglia
culture (top), and the large reduction of these in purified microglia (bottom). Predicted sizes
of products for each lane are in Table 1.
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Fig. 3. mRNA encoding P2Y12 and P2Y13 receptors in mouse brain
Gel of PCR products from adult mouse brain. The predicted sizes of the products for P2Y12
and P2Y13 are 939 bp and 1178 bp, respectively. The sequence of these products agreed >95%
with published sequences.
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Fig. 4. Real-time PCR of P2 receptor mRNA
Top: Amount of mRNA of indicated markers and receptors relative to actin from purified
microglia. Data mean ± S.D. Middle: Amount of mRNA relative to actin from mixed astrocyte/
microglia cultures from which purified microglia were harvested. Note break in scale to include
GFAP. Data mean ± S.D. Bottom: Amounts of mRNA in purified microglia relative to the
amount in mixed astrocyte/microglia both standardized to actin determined by the comparative
Ct method. Note the log scale, so that bars going up from 1 indicate increases in purified
microglia relative to mixed glial cultures, and bars going down from 1 indicate decreases. Each
experiment was in triplicate with the number of individual experiments in parentheses. *P ≥
0.05 compared with mRNA in mixed astrocyte/microglia cultures. Data mean ± S.D. (shown
in positive direction only because of the logarithmic scale).
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Fig. 5. Real-time PCR of P2 receptor mRNA in cerebral cortex and spinal cord
The amount of mRNA in cerebral cortex and spinal cord, relative to actin, from two mice
determined by the comparative Ct method. Each primer–probe set was run in triplicate. Note
that the relative amount of each P2 receptor is the same magnitude as that in mixed astrocyte/
microglia cultures. Data are mean ± S.D.
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Fig. 6. Dose-response curve for calcium responses to nucleotides from microglia 4 hours and 24
hours after plating
(A) Microglia plated for 4 hours. Each data point obtained from 3–6 separate experiments on
different multi-well plates, from different passages for each data point. Nucleotides were
applied at the concentrations indicated, as described in the methods. Positive responses were
set at fluorescence intensities exceeding the control values by at least two S.D.s for two
consecutive frames (see Methods). S.D.s are not shown here for clarity, but ranged from 0.02–
0.9. (B) Dose-response curves in microglia plated for 24 hours, plotted on same scale as (A).
Note the addition of BZATP and A2P4.
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Fig. 7. Calcium responses evoked by ATP are blocked by suramin but not by PPADS and responses
to three nucleotides are reduced by PTx
Top: In blocking experiments, either PPADS (100 μM) or suramin (100 μM) were applied for
5 minutes before application of ATP. Then 2 μM ATP + PPADS (n = 9) or 2 μM ATP + suramin
(n = 10) were added to evoke responses. *, P<0.001 (t-test, 2-tailed with unequal variance)
comparing ATP (n = 11) with ATP + suramin. Bottom: Calcium responses to nucleotides are
blocked by PTx (500 ng ml−1) for 1 hour before application of the indicated nucleotides. All
nucleotides were applied at 100 nM in observation medium containing 500 ng ml−1 PTx. *,
P<0.05 (t-test, 2-tailed with unequal variance) n = 6–7 for each agonist. Data are mean ± S.D.
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Fig. 8. Calcium responses to nucleotides are not blocked by the P2Y1 antagonist MRS 2179:
responses to high doses of ATP are blocked by o-ATP a P2X7 antagonist
Top: Nucleotides were applied at 100 nM for 2 MeSADP (n = 4), ADP (n = 4) and UTP (n =
4), and 2 μM for ATP (n = 5). In all experiments, MRS 2179 (30 μM) was applied 5 minutes
before and included with the nucleotide. Bottom: Effect of 450 μM o-ATP on the proportion
of microglia that respond to ATP. Microglia were pre-incubated in o-ATP for 2 hours and ATP
added to the culture wells (n = 3 in all experiments). *, P<0.01 (2-tailed, unequal variance t-
test). Data are mean ± S.D.
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Fig. 9. Shape changes evoked by application of agonists
Results of at least three experiments are included in each data point.
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Table 2
Taqman Gene-Expression Assay primer and probe sets for real-time PCR analyses (supplied by ABI)




Mm00434455_m1 Itgam Mac-1 CR3 receptor
Mm00445274_m1 Tlr4 Tlr-4
Mm00435471_m1 P2ry1 P2Y1 receptor
Mm00435472_m1 P2ry2 P2Y2 receptor
Mm00445136_s1 P2ry4 P2Y4 receptor
4331348 p2y6 custom p2y6 P2Y6 receptor
Mm00446026_m1 P2ry12 P2Y12 receptor
Mm00546978_m1 P2ry13 P2Y13 receptor
Mm01283360_m1 P2Y14 P2Y14 receptor
Mm00523699_m1 P2X3 P2X3 receptor
Mm00501787_m1 P2rx4 P2X4 receptor
Mm00473677_m1 P2X5 P2X5 receptor
Mm00440582_m1 P2X7 P2X7 receptor
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